JAN vs. DRRX, PMN, APLM, MRKR, CASI, BCTX, FBIO, VYNE, IPA, and BOLT
Should you be buying JanOne stock or one of its competitors? The main competitors of JanOne include DURECT (DRRX), ProMIS Neurosciences (PMN), Apollomics (APLM), Marker Therapeutics (MRKR), CASI Pharmaceuticals (CASI), BriaCell Therapeutics (BCTX), Fortress Biotech (FBIO), VYNE Therapeutics (VYNE), ImmunoPrecise Antibodies (IPA), and Bolt Biotherapeutics (BOLT). These companies are all part of the "pharmaceutical preparations" industry.
JanOne (NASDAQ:JAN) and DURECT (NASDAQ:DRRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, community ranking, earnings, profitability, institutional ownership, dividends and risk.
6.3% of JanOne shares are owned by institutional investors. Comparatively, 28.0% of DURECT shares are owned by institutional investors. 3.0% of JanOne shares are owned by company insiders. Comparatively, 4.3% of DURECT shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
JanOne has a beta of 2.04, suggesting that its share price is 104% more volatile than the S&P 500. Comparatively, DURECT has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500.
JanOne has a net margin of 0.00% compared to DURECT's net margin of -279.77%. DURECT's return on equity of -305.09% beat JanOne's return on equity.
JanOne has higher revenue and earnings than DURECT.
DURECT has a consensus target price of $27.50, indicating a potential upside of 2,842.75%. Given DURECT's higher probable upside, analysts plainly believe DURECT is more favorable than JanOne.
DURECT received 316 more outperform votes than JanOne when rated by MarketBeat users.
In the previous week, DURECT had 6 more articles in the media than JanOne. MarketBeat recorded 11 mentions for DURECT and 5 mentions for JanOne. JanOne's average media sentiment score of 0.23 beat DURECT's score of 0.05 indicating that JanOne is being referred to more favorably in the media.
Summary
DURECT beats JanOne on 8 of the 14 factors compared between the two stocks.
Get JanOne News Delivered to You Automatically
Sign up to receive the latest news and ratings for JAN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding JAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
